Gary L. Rosner
Affiliations: | Rice University, Houston, TX |
Area:
Statistics, Biostatistics BiologyGoogle:
"Gary Rosner"Children
Sign in to add traineeMeichun Ding | grad student | 2006 | Rice University |
Krzysztof J. Rudnicki | grad student | 2006 | Rice University |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
DeZern AE, Zahurak ML, Symons HJ, et al. (2020) Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide. Blood Advances. 4: 1770-1779 |
Henderson NC, Louis TA, Rosner GL, et al. (2018) Individualized treatment effects with censored data via fully nonparametric Bayesian accelerated failure time models. Biostatistics (Oxford, England) |
Paller CJ, Rudek MA, Antonarakis ES, et al. (2014) A phase I trial of muscadine grape skin in men with biochemically recurrent prostate cancer. Journal of Clinical Oncology. 32: 263-263 |
Hennessey VG, Rosner GL, Bast RC, et al. (2010) A Bayesian approach to dose-response assessment and synergy and its application to in vitro dose-response studies. Biometrics. 66: 1275-83 |
Eng C, Chang GJ, Das P, et al. (2009) Phase II study of capecitabine and oxaliplatin with concurrent radiation therapy (XELOX-XRT) for squamous cell carcinoma of the anal canal. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 4116 |
Hoskins JM, Rosner GL, Ratain MJ, et al. (2009) Pharmacodynamic genes do not influence risk of neutropenia in cancer patients treated with moderately high-dose irinotecan. Pharmacogenomics. 10: 1139-46 |
De Iorio M, Johnson WO, Müller P, et al. (2009) Bayesian nonparametric nonproportional hazards survival modeling. Biometrics. 65: 762-71 |
Davies SM, Borowitz MJ, Rosner GL, et al. (2008) Pharmacogenetics of minimal residual disease response in children with B-precursor acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood. 111: 2984-90 |
Ding M, Rosner GL, Müller P. (2008) Bayesian optimal design for phase II screening trials. Biometrics. 64: 886-94 |
Garcia-Manero G, Yang H, Bueso-Ramos C, et al. (2008) Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood. 111: 1060-6 |